Association of sociodemographic and clinical factors with the quality of life of Brazilian individuals with Neurofibromatosis type 1: a cross-sectional study

Background: Neurofibromatosis type 1 (NF1) is a rare genetic disorder with a wide range of clinical manifestations, notably neurocutaneous features, that can lead to emotional and physical consequences. Objectives: This study assessed the influence of sociodemographic factors and clinical features of the disease on the quality of life of Brazilian individuals with NF1. Methods: This is a descriptive cross-sectional study. Data were collected from 101 individuals with NF1 using the Brazilian version of the Impact of NF1 on Quality of Life Questionnaire (INF1QoL), a form with information on sociodemographic characteristics, and an NF1 visibility self- evaluation scale. The relationship between variables was evaluated through statistical testing, and the significance level was defined as 0.05. Results: The study included 101 adults with NF1 aged 18 to 59 years, with a mean age of 35.54 years (+/- 9.63) and a female predominance (n = 84, 83.17%). The mean total INF1-QoL score was 10.62 (+/- 5.63), with a median of 10, minimum value of 0, and maximum of 31 points. Two characteristics of the participants were significantly associated with the quality of life: educational level (p = 0.003) and familial history of NF1 (p = 0.019). There was a statistically significant correlation between the INF1-QoL score and the degree of disease visibility (rho = 0.218; p = 0.028). Study limitations: Cross-sectional study, conducted with a convenience sample and using self- reported measures. Conclusions: The findings support the significant impact of NF1 on quality of life. The authors recommend multidisciplinary follow-up for patients, with adherence to anticipatory clinical care measures, adequate pain control, psychological assistance, and genetic counseling. (c) 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana, a, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).